Hematology

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring collaboration, patient-centered strategies, and AI.

Despite improved selectivity, real-world data point to persistent cardiovascular challenges even with next-generation BTKi therapies.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients with multiple myeloma.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.

Cardiac adverse events were lower among patients taking zanubrutinib compared with ibrutinib in the real-world setting.

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Serum biochemical fingerprints can stratify chronic lymphocytic leukemia (CLL) outcomes and uncover heterogeneity within molecularly defined low-risk disease.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.

A novel combination therapy enhances the effectiveness of proteasome inhibitors against acute myeloid leukemia (AML), improving survival rates in preclinical models.

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

The LINKER-SMM1 trial shows promising results for linvoseltamab in treating high-risk smoldering multiple myeloma with a favorable safety profile, notes Paula Rodríguez-Otero, MD, PhD.

Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for optimal patient care.

Kelley L. Julian, PharmD, BCOP, discusses optimizing myeloma care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

Nanopore sequencing of chronic lymphocytic leukemia (CLL) may be a particularly good fit in under-resourced areas due to its lower cost and smaller laboratory footprint.

Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

Patients with immunoglobulin M-type monoclonal gammopathy did not experience a survival benefit from targeted therapies, a study found.

The MajesTEC-5 trial shows teclistamab's impressive efficacy in achieving MRD-negative status in newly diagnosed transplant-eligible patients, explains Marc S. Raab, MD, PhD.

Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for transplant or CAR T-cell Therapy.

Patients with essential thrombocythemia live with a risk of developing serious bleeding complications, a new study explains.

A case series suggests using minimal residual disease to trigger anti-CD20 therapy for chronic lymphocytic leukemia (CLL) can add years to some patients’ lives.

Patients with hematologic malignancies face ongoing survivorship challenges as providers struggle to coordinate care, according to Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.